Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00785577 · ClinicalTrials.gov registry record · Phase 2
A Study for Treatment of Pain in Patients With Diabetic Neuropathy.
A Phase 2 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 2
- Development phase
- 273
- Enrollment target
NCT00785577 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 273 participants.
The verdict
NCT00785577, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 273 participants
- Enrollment target
Study Summary
The purpose of this study is to test whether a new treatment will be safe and effective in treating pain. Patients with diabetic peripheral neuropathy will be included.
Interventions
- DRUG Placebo
- DRUG Pregabalin
- DRUG LY545694 49 mg
- DRUG LY545694 105 mg
- DRUG LY545694 21 mg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 273 participants |
| Start Date | 2008-11 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00785577
The ClinicalTrials.gov registry entry for NCT00785577 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 273 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT00785577 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00785577 about?
NCT00785577 is a clinical study titled "A Study for Treatment of Pain in Patients With Diabetic Neuropathy.". The purpose of this study is to test whether a new treatment will be safe and effective in treating pain. Patients with diabetic peripheral neuropathy will be included.
What is the current status of trial NCT00785577?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 273 participants. The study started on 2008-11. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00785577?
The interventions under investigation include: Placebo (DRUG), Pregabalin (DRUG), LY545694 49 mg (DRUG), LY545694 105 mg (DRUG), LY545694 21 mg (DRUG).
Who is sponsoring clinical trial NCT00785577?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.